Significados de selective estrogen en inglés

Different chemoprevention trials are ongoing to compare different selective estrogen receptor modulators and aromatase inhibitors with tamoxifen.

Therefore, 6-DMAN is an exciting candidate molecule for future investigations and potentially a natural occurring selective estrogen receptor modulator.

Raloxifene is a selective estrogen receptor modulator that may delay the onset of mild cognitive impairment in elderly women.

Clomiphene citrate, a selective estrogen receptor modulator, has been used to treat infertility in women and men for 50 years.

Background: Tamoxifen is a selective estrogen-receptor modulator shown to improve several cardiovascular risk factors in postmenopausal women with breast cancer.

While the estrogen treatment of stroke is under debate, selective estrogen receptor modulators (SERMs) arise as a promising alternative.

Objective: To investigate the short-term effects of HMR 3339, a novel selective estrogen receptor modulator, on markers of coagulation and fibrinolysis.

The design of a novel selective estrogen receptor modulator (SERM) for the potential treatment of uterine leiomyoma is described.

Sales of the drug, a selective estrogen receptor modulator, topped $1 billion in 2006.

These findings make 6-DMAN a very interesting candidate substance for further characterization, as it potentially represents a naturally occurring selective estrogen receptor modulator.

Estrogens and selective estrogen receptor modulators (SERMs) have been shown to promote or inhibit prostate proliferation signifying potential roles in BPH.

Tamoxifen, a selective estrogen-receptor modulator, is widely used in mouse models to temporally control gene expression but is also known to affect body composition.

Completed large studies with the classical selective estrogen receptor modulator (SERM) tamoxifen have demonstrated that preventing breast cancer pharmacologically is now possible.

Fablyn belongs to a class of drugs known as selective estrogen receptor modulators, or SERMs, which includes Eli Lilly and Co's osteoporosis drug Evista.

The drug company also said it received a second approvable letter from the U.S. Food and Drug Administration for bazedoxifene, a selective estrogen receptor modulator.

Improved hormone formulations and selective estrogen receptor modulators that help to maintain vascular function and limit progression of cardiovascular occlusive disease need to be developed.